

MEETING ABSTRACT

Open Access

Treatment guidelines for acute bipolar depression

Konstantinos N Fountoulakis

From 1st International Congress on Neurobiology and Clinical Psychopharmacology and European Psychiatric Association Conference on Treatment Guidance
Thessaloniki, Greece. 19-22 November 2009

Bipolar depression is the facet of bipolar disorder most difficult to treat and responsible for most of the disability related to bipolar disorder. Despite supposedly being evidence-based, guidelines for the treatment of bipolar disorder vary significantly across committees or working groups. While the usefulness of quetiapine, the olanzapine-fluoxetine combination, lithium, valproic acid and carbamazepine is widely accepted, it is clearly stated that in bipolar depression antidepressants should be used only in combination with antimanic agents in order to avoid switching of phases. However there is still controversy over the usefulness of the various agents and modalities mainly due to little and poor evidence and conflicting opinions.

Published: 22 April 2010

doi:10.1186/1744-859X-9-S1-S63

Cite this article as: Fountoulakis: Treatment guidelines for acute bipolar depression. *Annals of General Psychiatry* 2010 **9**(Suppl 1):S63.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

